148 related articles for article (PubMed ID: 31668277)
1. Testing Immune-Related Adverse Events in Cancer Immunotherapy.
Farmer JR
Clin Lab Med; 2019 Dec; 39(4):669-683. PubMed ID: 31668277
[TBL] [Abstract][Full Text] [Related]
2. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.
Bertrand A; Kostine M; Barnetche T; Truchetet ME; Schaeverbeke T
BMC Med; 2015 Sep; 13():211. PubMed ID: 26337719
[TBL] [Abstract][Full Text] [Related]
3. Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.
Kehl KL; Yang S; Awad MM; Palmer N; Kohane IS; Schrag D
Cancer Immunol Immunother; 2019 Jun; 68(6):917-926. PubMed ID: 30877325
[TBL] [Abstract][Full Text] [Related]
4. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
5. Neurological Immunotoxicity from Cancer Treatment.
Wesley SF; Haggiagi A; Thakur KT; De Jager PL
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Toxicity Management in Clinical Practice: Building the Clinical Infrastructure for Immune-related Adverse Event Evaluation and Care.
Klionsky Y; Simon Meara A; Reid P
Rheum Dis Clin North Am; 2024 May; 50(2):229-239. PubMed ID: 38670722
[TBL] [Abstract][Full Text] [Related]
7. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy.
Young A; Quandt Z; Bluestone JA
Cancer Immunol Res; 2018 Dec; 6(12):1445-1452. PubMed ID: 30510057
[TBL] [Abstract][Full Text] [Related]
8. Strategies for improving the management of immune-related adverse events.
Naing A; Hajjar J; Gulley JL; Atkins MB; Ciliberto G; Meric-Bernstam F; Hwu P
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33310772
[TBL] [Abstract][Full Text] [Related]
9. An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition.
Naidoo J; Dykema A; D'Alessio F
J Clin Invest; 2019 Jan; 129(1):75-77. PubMed ID: 30530990
[TBL] [Abstract][Full Text] [Related]
10. [Imaging in immunotherapy for tumor diseases].
Sedlaczek O
Radiologie (Heidelb); 2024 Jan; 64(1):69-80. PubMed ID: 38189933
[TBL] [Abstract][Full Text] [Related]
11. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.
Darnell EP; Mooradian MJ; Baruch EN; Yilmaz M; Reynolds KL
Curr Oncol Rep; 2020 Mar; 22(4):39. PubMed ID: 32200442
[TBL] [Abstract][Full Text] [Related]
12. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
Pan PC; Haggiagi A
Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691
[TBL] [Abstract][Full Text] [Related]
13. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.
Das S; Johnson DB
J Immunother Cancer; 2019 Nov; 7(1):306. PubMed ID: 31730012
[TBL] [Abstract][Full Text] [Related]
14. Immunologic adverse events from immune checkpoint therapy.
Richter MD; Hughes GC; Chung SH; Ezeanuna M; Singh N; Thompson JA
Best Pract Res Clin Rheumatol; 2020 Aug; 34(4):101511. PubMed ID: 32299675
[TBL] [Abstract][Full Text] [Related]
15. Moving towards personalized treatments of immune-related adverse events.
Esfahani K; Elkrief A; Calabrese C; Lapointe R; Hudson M; Routy B; Miller WH; Calabrese L
Nat Rev Clin Oncol; 2020 Aug; 17(8):504-515. PubMed ID: 32246128
[TBL] [Abstract][Full Text] [Related]
16. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance.
Raschi E; Gatti M; Gelsomino F; Ardizzoni A; Poluzzi E; De Ponti F
Target Oncol; 2020 Aug; 15(4):449-466. PubMed ID: 32725437
[TBL] [Abstract][Full Text] [Related]
17. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis.
von Itzstein MS; Khan S; Gerber DE
Clin Chem; 2020 Jun; 66(6):779-793. PubMed ID: 32363387
[TBL] [Abstract][Full Text] [Related]
18. A review of cancer immunotherapy toxicity.
Kennedy LB; Salama AKS
CA Cancer J Clin; 2020 Mar; 70(2):86-104. PubMed ID: 31944278
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Weinmann SC; Pisetsky DS
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
[TBL] [Abstract][Full Text] [Related]
20. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
